Treatment of neurodegenerative disease through intracranial delivery of SIRNA
The present invention provides devices, small interfering RNA, and methods for treating a neurodegenerative disorder comprising the steps of surgically implanting a catheter so that a discharge portion of the catheter lies adjacent to a predetermined infusion site in a brain, and discharging through the discharge portion of the catheter a predetermined dosage of at least one substance capable of inhibiting production of at least one neurodegenerative protein. The present invention also provides valuable small interfering RNA vectors, and methods for treating neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, Huntington's disease, Spinocerebellar Ataxia Type 1, Type 2, Type 3, and/or dentatorubral-pallidoluysian atrophy.
1. An isolated RNA interference agent comprising:
a) a first strand having length between 19 and 30 nucleotides and comprising SEQ ID NO: 1; and
b) a second strand having length between 19 and 30 nucleotides and comprising SEQ ID NO: 2.
2. The isolated RNA interference agent of claim 1 , wherein the first and the second strand are connected by a loop.
3. The isolated RNA interference agent of claim 1 comprising at least one modified nucleotide.
4. A vector encoding the isolated RNA interference agent of claim 1 .
5. The vector of claim 4 comprising a polIII promoter.
6. The vector of claim 5 , wherein the polIII promoter is a U6 or HI promoter.
7. The vector of claim 4 , which is a viral vector.
8. The vector of claim 7 , which is an adeno-associated viral vector.
9. A pharmaceutical composition comprising the isolated RNA interference agent of claim 1 or a vector encoding said isolated RNA interference agent.
10. The pharmaceutical composition of claim 9 comprising the vector encoding said isolated RNA interference agent complexed with liposomal compounds or polyethyleneamine.
11. The isolated RNA interference agent of claim 1 , wherein the first strand consists essentially of the sequence of SEQ ID NO: 1 and the second strand consists essentially of the sequence of SEQ ID NO: 2.
12. The isolated RNA interference agent of claim 11 , wherein the first strand consists of the sequence of SEQ ID NO: 1 and the second strand consists of the sequence of SEQ ID NO: 2.